Viking Therapeutics (VKTX) Income from Continuing Operations (2014 - 2026)
Viking Therapeutics (VKTX) posted Income from Continuing Operations of 263896000.0 for Q2 2026, up 0.93% sequentially from 266375000.0 in Q1 2026, and down 74.59% YoY from 1038402662.57 in Q2 2025.
Viking Therapeutics (VKTX) Income from Continuing Operations (2014 - 2026) Analysis & Trends
Viking Therapeutics has reported Income from Continuing Operations for 13 years, with the latest figure at 263896000.0 in Q2 2026.
- Quarterly Income from Continuing Operations fell 74.59% year-over-year to 263896000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 982035000.0 (down 27.03% YoY) and the FY2025 annual result came in at 506223000.0, down 60.61% from the prior year.
- Income from Continuing Operations rose to 263896000.0 in Q2 2026 per VKTX's latest filing, from 266375000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 17848000.0 in Q3 2022 and troughed at 60347036000.0 in Q1 2023.
- A 5-year average of 7553315702.28 and a median of 235082820.5 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations plunged 318707.31% in 2023, then soared 99.48% in 2024.
- Over 5 years, Income from Continuing Operations stood at 40280000.0 in 2022, then tumbled by 126.06% to 91058000.0 in 2023, then tumbled by 133.47% to 212590000.0 in 2024, then sank by 31.12% to 278748000.0 in 2025, then climbed by 5.33% to 263896000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 263896000.0, 266375000.0, and 278748000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Viking Therapeutics | 3.87 Bn | 3.87 Bn | - | -263.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -263.90 Mn |
| Mar 31, 2026 | -266.38 Mn |
| Dec 31, 2025 | -278.75 Mn |
| Sep 30, 2025 | -173.02 Mn |
| Jun 30, 2025 | -151.16 Mn |
| Mar 31, 2025 | -121.30 Mn |
| Dec 31, 2024 | -212.59 Mn |
| Sep 30, 2024 | -288.03 Mn |
| Jun 30, 2024 | -257.58 Mn |
| Mar 31, 2024 | -436.20 Mn |
| Dec 31, 2023 | -91.06 Mn |
| Sep 30, 2023 | -23.36 Bn |
| Jun 30, 2023 | -49.62 Bn |
| Mar 31, 2023 | -60.35 Bn |
| Dec 31, 2022 | -40.28 Mn |
| Sep 30, 2022 | -17.85 Mn |
| Jun 30, 2022 | -19.45 Mn |
| Mar 31, 2022 | -18.93 Mn |
| Dec 31, 2021 | -15.77 Mn |
| Sep 30, 2021 | -18.95 Mn |